Once activated, PAR2 also determines JNK 1/2 phosphorylation which inhibits insulin signaling, resulting in insulin resistance and subsequent liver steatosis associated with increased gluconeogenesis, through the activation of the lipogenic-regulatory transcription factor SREBP-1c (75). This evidence concerns the gene INS and fatty liver disease.